

Abstract submission process on the MyICML online platform

 www.myaccount.icml.ch/login


MyICML

Email

Password


[Reset password](#)

Remember me

 Login



If you already have a MyICML account, just login

 Create a new account



If it's the first time on MyICML, follow the instructions to create a new account

You need to create the MyICML account for:

- registration to the 17-ICML
- registration to the ICML-ESMO course
- abstract submission to 17-ICML

Steps to create a new account:

1

Enter your email address:

Check email

MyICML account:
Check email

Enter your email address here to check if it has already been saved in our system

Email

2

Complete an online form and create a password:

MyICML

MyICML account:

Please complete all the required fields. Fields marked with an asterisk (*) are mandatory.

To be sure to receive the confirmation email of the MyICML account and the communications pertinent to 17-ICML and ICML-ESMO Full Immersion Course please add info@icml.ch, registration@icml.ch and abstract@icml.ch and course@icml.ch to your address book.

Salutation

Select one option

First Name* Middle name Last Name*

Gender

Male Female Other

Email*

Work Phone Mobile Phone

Work Place* Department

Name of Institution, Hospital, Company etc. or Private practice

Country*


3

The account is created and a message will be sent to the email address in order to be confirmed.

MyICML
confirmed

Save and create a MyICML account→

Steps to successfully submit an abstract:



MY REGISTRATIONS



17-ICML Conference

ICML-ESMO Course

My Abstract Submission

My account details


My Abstract Workplace

My abstract submission

 + New Abstract

First, you should indicate if you are the presenter or if you submit the abstract on behalf of the presenter (i.e. you are the submitter):

 I am the presenter

 I am not the presenter*

Steps to successfully submit an abstract: 1/8

Presenter affiliation and responsibilities

Fill in the requested information:

Both the presenter and the submitter must accept the abstract submission' responsibilities:

Presenter information

Salutation
Select one option

First Name* Middle Name Last Name*
Stéphanie Pedrioli

Gender
 Male Female Other

Presenter Email* Other Email
stephanie.pedrioli@icml.ch
all notifications will be also sent to "Other Email", if provided

Work Phone Mobile Phone



- Responsibilities***
- **Presenter** → As presenter of the abstract I am submitting, I accept the 17-ICML presenter responsibilities. Presenter responsibilities
 - **Submitter** → As submitter, I confirm that the first author is fully informed of this submission and his/her responsibilities. Presenter responsibilities

This is the first step out of eight. They should not be completed in a specific order, but all are mandatory:




Steps to successfully submit an abstract: 2/8

Abstract title

DO NOT enter the title in UPPERCASE letters. Please use sentence-style capitalization (capitalize the first word and lowercase the others, unless they are proper nouns and acronyms).


Max characters: 150

Current characters:



A rich text editor interface for entering an abstract title. The toolbar at the top includes icons for undo, redo, paste, insert link, italic (*I*), bold (**B**), italic (*I*), underline (U), subscript (x_2), superscript (x^2), bulleted list, numbered list, decrease indent, and increase indent. Below the toolbar is a large, empty text input area.

Back

 Save and Preview

Steps to successfully submit an abstract: 3/8

Abstract options:

* EA - Encore Abstract

the pertinent sentence will be added to the text: "EA – previously submitted to regional or national meetings with ≤ 1'000 attendees / EBMT / AACR / ASCO / EHA 2023"

- EBMT 2023
- AACR 2023
- ASCO 2023
- EHA 2023
- Regional or national meeting (≤ 1'000 attendees)

* Travel Grant

- If my abstract is accepted for oral or poster presentation, I am eligible for a young investigator travel grant (I am 35 years old or younger).

Travel grants and merit award +

* Withdrawal option

- If the abstract is selected for publication only (inclusion in the 17-ICML Abstract Book but NO oral and NO poster presentation) I wish to withdraw it. **No withdrawal request will be accepted if received after the deadline of the abstract submission (March 15, 17:59 CET).**

* Preference

Preference of presentation

- No preference
- Oral presentation
- Poster presentation

The Organizing Committee reserves the right to conclusively decide the presentation format, based on the evaluation results and the Scientific Program structure.

Back

* Research funding disclosure

- "The research was funded by: ..."

* Updated analysis

- Previous publication and novel information since it (This note will not be published, but only transmitted to reviewers):

max 350 characters

* Ongoing Trial

- The abstract will include only the INTRODUCTION and METHODS sections.

Ongoing Trials abstracts +

Steps to successfully submit an abstract: 4/8

Conflict of interest


Disclosure of conflict of interest: Cristiana Brentan

No conflicts of interests pertinent to the abstract to be declared

Disclosure of any conflict of interest related to the data presented in the abstract is mandatory. Authors must declare the name of the company they maintain a "relevant financial relationship" with.

"Relevant financial relationships" are intended those relationships from which they or any individual with whom they directly share their income have received or may receive financial benefit within the past 24 months. The relationships that must be declared are: employment or leadership position in a company – consultant or advisory role - stock ownership – honoraria – research funding – travel grants – other remuneration.

Please indicate any conflict of interest related to the data presented in the abstract



No conflicts of interests pertinent to the abstract to be declared

Disclosure of any conflict of interest related to the data presented in the abstract is mandatory. Authors must declare the name of the company they maintain a "relevant financial relationship" with.

"Relevant financial relationships" are intended those relationships from which they or any individual with whom they directly share their income have received or may receive financial benefit within the past 24 months. The relationships that must be declared are: employment or leadership position in a company – consultant or advisory role - stock ownership – honoraria – research funding – travel grants – other remuneration.

Employment or leadership position

Consultant or advisory role

Stock ownership

Honoraria

Research funding

Travel grants

Other remuneration

Steps to successfully submit an abstract: 5/8

Co-authors


Coauthor information

Salutation
Select one option

First Name* Middle name Last Name*

Gender
 Male Female Other

Authors will be listed with first and middle name initials, surname, institution, department, city and country



There is no limit to the number of listed co-authors.

It is possible to move/drag the authors to the desired order.
Conflict of interests pertinent to the abstracts must be declared for each author (presenter and co-authors).

Stéphanie Pedrioli PRESENTER

Emanuele Zucca Conflicts

Cristiana Brentan Conflicts

+ Add coauthor

Back Save and Preview

Author(s):
S. Pedrioli¹, E. Zucca², C. Brentan¹
¹ Foundation for the Institute of Oncology Research (IOR), Bellinzona, Switzerland
² IELSG, Bellinzona, Switzerland

Steps to successfully submit an abstract: 6/8

Abstract text

* Max characters: 2500

All abstracts (except for ongoing trials abstracts) should include the following four sections:

1. Introduction, 2. Methods, 3. Results, 4. Conclusions

Compounds should be mentioned with the generic name in lower case.


Commercial names must not be used.

Abbreviations are permitted but terms must be spelt out at their first mention and followed by the abbreviation in parentheses, i.e. International Conference on Malignant Lymphoma (ICML).

Once the abstract has been submitted, *corrigenda* (corrections, rewording or amendments in the text and change of order in the authors' string) will not be possible.

Abstract image

- * Only **one** JPEG, GIF or PNG file can be uploaded, with the following resolution criteria:
 - Graphs and tables: 800 dpi preferred; 600 dpi minimum;
 - Images: 300 dpi minimum.
 - The system accepts only one file, up to 50 MB.



Steps to successfully submit an abstract: 7/8

Abstract category

Please add up to 3 categories:

Basic and Translational Science

- Bioinformatics; Computational and Systems Biology
- Genomics, Epigenomics, and Other -Omics
- Metabolism
- Patient-Derived Xenograft (PDX) Models
- Risk Models
- Tumor Biology and Heterogeneity
- Other
- Microenvironment

Pathology and Classification of Lymphomas

- Pathology and Classification of Lymphomas

Prevention and Cancer Interception

- Prevention and Cancer Interception

Cancer Health Disparities

- Cancer Health Disparities

Diagnostic and Prognostic Biomarkers

- Diagnostic and Prognostic Biomarkers

Experimental Therapeutics

- Cellular therapies
- Chemotherapy
- Molecular Targeted Therapies
- Combination Therapies
- Immunotherapy
- Radiation Therapy
- Targeting the Tumor Microenvironment
- Other

Lymphoid Cancers

- Aggressive B-cell non-Hodgkin lymphoma
- Aggressive T-cell non-Hodgkin lymphoma
- Canine Lymphoma as a Surrogate
- Chronic Lymphocytic Leukemia (CLL)
- Cutaneous non-Hodgkin lymphoma
- Extranodal non-Hodgkin lymphoma
- Hodgkin lymphoma
- Indolent non-Hodgkin lymphoma
- Multiple Myeloma
- Non-Hodgkin (Pediatric, Adolescent, and Young Adult)
- Other

Imaging and Early Detection

- PET-CT
- Liquid biopsy
- Minimal residual disease
- Other

Late Effects in Lymphoma Survivors

- Late Effects in Lymphoma Survivors

Therapeutics and Clinical Trials in Lymphoma

- Cellular therapies
- Chemotherapy
- Molecular Targeted Therapies
- Combination Therapies
- Immunotherapy
- Radiation Therapy
- Stem Cell Transplant
- Targeting the Tumor Microenvironment
- Other

Ongoing Trials

- Ongoing Trials

Other

- Other

Steps to successfully submit an abstract: 8/8

Preview and submission:

Before submission, the abstract is listed PENDING and can be modified (button "Manage" in "My Abstract Submission" list).

Upon submission, the presenter will receive an email confirmation of the submission.

Once submitted, the abstract is listed SUBMITTED and can be viewed online (button "View" in "My Abstract Submission" list).

It will not be possible to make any modifications.

Only abstracts submitted within the deadline will be considered and evaluated by the reviewers.



Nov 09, 2022
ID: AS510

Submission by **Presenter**

Status: **PENDING**

Manage



Dec 02, 2022
ID: AS520

Test
Submission by **Presenter**

Status: **SUBMITTED**

View

